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Abstract
Background: Cashews, as the main source of monounsaturated (MUFAs) and polyunsaturated (PUFAs) fatty acids, are associated
with reduced risk of cardiovascular diseases. Despite evidence for beneficial effects of nuts on lipid profile and glycemic control, to
the authors’ best knowledge, little is known about cashews.
Methods: An eight-week, randomized, isocaloric, controlled-feeding study was conducted on 50 patients with type 2 diabetes melli-
tus (T2DM) randomly assigned to either the control or intervention group (10% of total calorie from cashews). Weight, fasting plasma
glucose (FPG), serum insulin concentration and sensitivity, lipid profile ratio, high-sensitive C-reactive protein (hs-CRP), total antiox-
idant capacity (TAC), and paraoxonase-1 (PON-1) were measured at baseline and after eight weeks of intervention adjusted for age,
gender, baseline values of FPG, insulin, HOMA-IR (homeostatic model assessment of insulin resistance), fiber, and both baseline and
post-intervention vitamin C levels as covariates.
Results: Weight, body mass index (BMI), and waist circumference (WC) were not significantly different in the groups after eight
weeks of intervention, as well as between the two groups, compared with the baseline measures. At the end of the study, serum
insulin and low-density lipoprotein-cholesterol-to-high-density lipoprotein-cholesterol (LDL-C/HDL-C) ratio significantly decreased
in the cashews group compared with those of the controls (P = 0.01 and P = 0.04, respectively). Although, HOMA-IR decreased sig-
nificantly in the cashews group (P = 0.03), changes were not significant compared with the baseline measures (P = 0.056). Despite
more increase in PON-1 activity in the cashews group, the changes were not statistically significant.
Conclusions: Daily consumption of cashews reduced serum insulin and LDL-C/HDL-C ratio in patients with T2DM. However, further
studies with larger sample sizes and more duration are needed to confirm the current study results.
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1. Background
Type 2 diabetes mellitus (T2DM) and its complications
increase the risk of cardiovascular disease (CVD) (1). Diet
can reduce the vascular complications of diabetes. Dietary
components play important roles in the susceptibility to
chronic diseases especially type 2 diabetes and CVD (2). Pre-
vious clinical trials and epidemiologic studies show that
nuts such as pistachio, hazelnut, almond, macadamia, and
especially walnut have beneficial effects on various media-
tors of chronic diseases including lipid concentration, in-
flammation, insulin resistance, and blood pressure (BP)
(3-5). Studies on cashews are scarce and have inconclu-
sive results (6, 7). There is an inverse association between
nut consumption and diabetes, as well as CVD. But, weight
gain due to high fat and energy dense content, especially
cashews, is a concern (3). Then, it is important to assess the
association between cashews and weight changes, as well
as disease control to reach conclusive results to make com-
mendations.
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2. Objectives
The current study aimed at assessing the effects of
cashews consumption by substituting for 10% of daily
calorie intake with reduction in portion size of the fatty
foods such as red meat and the amount of visible fats
(oil, margarine, and butter) on body mass index (BMI),
waist circumference (WC), atherogenic indices including
total cholesterol (TC)/high-density lipoprotein-cholesterol
(HDL-C), low-density lipoprotein-cholesterol-to-HDL-C
(LDL-C/HDL-C), triglyceride (TG)/HDL-C ratio, high-sensitive
C-reactive protein (hs-CRP), and homeostatic model as-
sessment of insulin resistance (HOMA-IR), as well as total
antioxidant capacity (TAC) and paraoxonase-1 (PON-1) in
patients with T2DM.
3. Methods
3.1. Study Participants and Recruitment
Fifty male and female patients with T2DM were se-
lected from the individuals attending the Institute of En-
docrinology and Metabolism, Iran University of Medical
Sciences, Tehran, Iran. Inclusion criteria were age 30 - 75
years, BMI < 35 kg/m2, fasting plasma glucose (FPG) ≥ 126
mg/dL, two-hour plasma glucose (2h-PG)≥ 200 mg/dL, gly-
cosylated hemoglobin (HbA1C) 7% - 9%, serum LDL-C < 200
mg/dL, TG < 400 mg/dL, and BP ≤ 160/90 mmHg. The ex-
clusion criteria were allergy to nuts, insulin therapy, smok-
ing, history of stroke, heart diseases or thyroid dysfunc-
tion, nephropathy or retinopathy, medications that could
affect body weight and/or energy expenditure, consump-
tion of nuts more than twice per week, vegetarians, and
weight-loss diets up to two months before the enrollment
in the study. The study was approved by the Ethical Com-
mittee of Iran University of Medical Sciences, Tehran, Iran
(code: 244/P26/M/T). All patients signed consent form be-
fore participation in the study. The current study was reg-
istered at ClinicalTrials.gov (No. IRCT138812252709N5).
3.2. Study Design and Intervention
The current randomized, controlled-feeding trial was
designed to assess the effects of cashews consumption on
weight, FPG, serum insulin concentration and sensitivity,
lipid profile ratio, hs-CRP, TAC, and PON-1 in patients with
T2DM. Eligible participants were randomly assigned using
randomization method. Fifty patients were randomly as-
signed to one of the control (n = 25) or the cashews (n = 25)
groups receiving10% of total calorie from cashews per day
for eight weeks.
At first, 24-hour dietary recall forms were completed
in three days (two regular days and one holiday) by a di-
etitian. These dietary intake data were analyzed by the N4
software (Nutritionist 4, First Databank Division, Hearts
Corporation). All measures were recorded at the baseline
and after eight weeks in the two groups.
Blood samples were collected from the antecubital
vein after fasting (10 - 12 hours), at the baseline, and eight
weeks for biochemical analyses. After centrifugation for
15 minutes at 2500 g, the serum samples were frozen and
stored at -80°C. All the participants were asked not to alter
their medicine type and dosage during the test period. FPG
and lipid profile were measured by an enzymatic method
(Pars Azmoon Co. kit, Tehran, Iran). Insulin was mea-
sured by IRMA method (Immunotech Co. kit); homeosta-
sis model assessment was employed for insulin resistance
(HOMA-IR) (8) [fasting insulin (mU/L) × FPG (mM/L)]/405.
TAC was determined using FRAP assay according to the
method of Benzie and Strain (9). PON-1 activity was mea-
sured using the commercially available kit of Rel Assay Di-
agnostics (Gaziantep, Turkey) (10).
3.3. Diet and Physical Activity Planning
The intervention group was asked to substitute 10% of
their total calorie intake with cashews (~ 28 g/day, based
on baseline calculated energy intake). It was achieved by
reducing the portion size of the fatty foods such as red
meat and the amount of visible fats (oil, margarine, and
butter). This strategy allows cashews to be taken as snacks
without increase in total calorie intake (11). Using this
method, the subjects were asked not to make changes in
their total daily energy intake. Also, the control group was
asked not to change their dietary pattern. For each pa-
tient, according to the calculated daily energy intake, the
required amount of unsalted cashews was determined and
weighed by a digital scale (Beurer, model DS81). At the first
visit of the patients, a predefined amount of cashews was
given to each patient sufficient for a four-week period. At
the end of the first month, an extra 100 g of cashews was
delivered to each patient to increase the compliance of par-
ticipants. All needed instructions were provided by a nutri-
tionist for each subject, individually.
The International Physical Activity Questionnaire
(IPAQ) was used to measure physical activity level (PAL)
and all patients were advised not to change PAL. Compli-
ance was monitored once a week by telephone call and
double checked by the three day food record question-
naire that was completed twice during the study period (at
baseline and the end of the 8th week of the intervention).
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3.4. Statistical Analyses
With considering a power of 80% andα= 0.05 (type I er-
ror), as well as mean difference of 17.4 mg/dL for TC and 8.51
mg/dL for LDL-C reported in similar studies (12), the num-
ber of needed subjects was 22 in each group. Given an an-
ticipated dropout rate of 10%, the enrollment target was set
to 25 subjects.
All data were expressed by mean ± standard deviation
(SD). The level of significance was set at P < 0.05. Statisti-
cal analysis was performed with SPSS version 15 (SPSS, Inc.).
Normal distribution of the variables was checked by the
Kolmogorov-Smirnov test. Independent t test was used to
assess whether the differences between the mean values of
the items studied in the groups were significant. The com-
parison of mean values of variables before and after the in-
tervention in each group was examined by the paired sam-
ples t test. Analysis of covariance (ANCOVA) was performed
for the changes of biochemical values by considering age,
gender, baseline values of FPG, insulin, HOMA-IR, fiber, and




Out of the 50 patients with T2DM, 43 subjects com-
pleted the study (nine males and 34 females; mean age
53.86 ± 7.22 years) (Figure 1). Gender distribution was as
follows: Seven males and 15 females in the cashews group;
two males and 19 females in the control group. No dif-
ferences in gender and age distribution were observed be-
tween the two studied groups.
Energy and nutrient intake were not significantly dif-
ferent at the baseline between the groups, except vitamin
C and fiber intake (P = 0.006 and P = 0.02, respectively) (Ta-
ble 1). PAL was not different between the groups at the base-
line, as well as the end. At baseline, there were no statis-
tically significant differences in anthropometric and bio-
chemical measures between the groups (Table 2).
4.2. Diet, Anthropometric, and Biochemical Measures After an
Eight-Week Intervention
Post-intervention analyses showed that except for mo-
nounsaturated fatty acid (MUFA) (P = 0.005), vitamins E (P
< 0.001) and C (P = 0.018), other dietary components did
not differ between the cashews and control groups (Table
1). Weight, BMI, and WC had no significant difference at the
end of the study compared with the baseline measures (Ta-
ble 2). HOMA-IR (P = 0.03), TC/HDL-C (P = 0.04), and LDL-
C/HDL-C (P = 0.02) were significantly lower in the cashews
than the control group at the end. No significant differ-
ences were observed in TG/HDL-C, hs-CRP, and TAC levels be-
tween the two studied groups (P = 0.52, P = 0.46, and P =
0.34, respectively).
Despite the greater increase in PON-1 activity in the
cashews group, the intergroup difference was not statisti-
cally significant. Moreover, no significant difference was
observed between the two groups after eight weeks of in-
tervention (P = 0.41).
Using age, gender, baseline values of FPG, insulin,
HOMA-IR, fiber, and both baseline and post-intervention vi-
tamin C levels as covariates, serum insulin level was signif-
icantly lower in the cashews group compared with that of
controls (P = 0.01), but HOMA-IR was not significantly dif-
ferent (P = 0.13). LDL-C/HDL-C ratio was significantly differ-
ent, adjusted for baseline measures as covariates (P = 0.04).
5. Discussion
The current study results demonstrated that replacing
10% of daily total energy intake with unsalted cashews re-
duced serum insulin and LDL-C/HDL-C ratio (as an athero-
genic index) in patients with T2DM.
Few studies focused on the effects of different nuts con-
sumption on diabetes and the published results are incon-
clusive. One study found that almond consumption (57 -
113 g/day) for four weeks had no effect on FPG and insulin
status in patients with T2DM (13), while another one could
not find any significant effect by incorporation of 30 g/day
walnut into a healthy diet in patients with T2DM (14). This
difference may be due to the time and amount of nuts in
diets. Li et al. reported that a diet enriched with ~ 56 g/day
almonds in patients with T2DM could effectively decrease
FPG and insulin after four weeks. The HOMA-IR was signif-
icantly lower in the almond group (15). A high statistical
power study with patients at high risk for CVD, half of pa-
tients with T2DM, revealed that following a Mediterranean
diet including 30 g/day of mixed nuts intake (15 g walnut,
7.5 g almond, and 7.5 g hazelnut) could reduce FPG, in-
sulin, and HOMA-IR during three months when compared
with a low-fat diet (16). The decrease could be explained
by the unique nutrient composition and bioactive com-
pounds, as well as unsaturated fatty acids (MUFAs and PU-
FAs) present in cashews, which may play an important role
in insulin and lipid profile control. Also, fiber and polyphe-
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Figure 1. Screening, enrollment, random assignment, and follow-up of the study participants
nols may have anti-diabetic effects by regulating micro-
biome and lipid profile ratio (17-19).
The current study found that cashews could improve
LDL-C/HDL-C ratio in patients with T2DM. The current study
results were in agreement with those of a randomized,
crossover, isocaloric, controlled-feeding study, in which
consumption of cashew nuts reduced TC, LDL-C, and non-
HDL-C serum levels as well as TC/HDL-C ratio (7). Nuts,
including cashews have unique nutrient contents, which
can favorably affect lipid profile (3, 20, 21) in patients with
T2DM (15).
In the current study, TAC had no significant difference
between the cashews and the control groups after eight
weeks. The obtained results were in agreement with those
of another study in which consumption of 30 g/day wal-
nut for six months had no significant effects on TAC in pa-
tients with T2DM (14). Also, a study showed that incorpo-
ration of cashews or walnuts into the diet for eight weeks
had no significant effect on plasma level of TAC in patients
with metabolic syndrome (8). Based on the published stud-
ies, it seems that using TAC as a single marker of antioxi-
dant status does not provide promising results. Some stud-
ies that used other markers of antioxidant status demon-
strated that antioxidant effects of nuts were not limited
to the improvement of TAC. Malondialdehyde (MDA) con-
centration as a marker of lipid peroxidation decreased in
some studies using almond (22), walnut (23), or pecan (24).
Nuts such as cashews are rich sources of antioxidants (25).
Therefore, it seems reasonable to expect to be effective in
antioxidant status. However, simultaneous use of several
indices can provide more comprehensive results.
In the current study, no beneficial effect of cashews
consumption was detected on hs-CRP level. A 12-week feed-
ing trial revealed that incorporation of raw-mixed nuts (15
g walnuts, 7.5 g almonds, and 7.5 g hazelnuts) into the diet
could not influence the inflammatory biomarkers such as
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Table 1. Dietary Information of the Study Groupsa
Dietary Intake Control (N = 21) Cashews (N = 22) P Valueb
Before Intervention After Intervention Before Intervention After Intervention
Total energy, kcal 1536 ± 73.6 1640.1 ± 206.2 1725.8 ± 524.1 1687 ± 428.6
0.5
P valuec 0.72 0.5
Total protein, g/d 62.6 ± 21 65 ± 23.1 63.5 ± 23.8 64.8 ± 22.7
0.46
P value 0.8 0.1
Carbohydrate, g/d 222.2 ± 54.5 236.3 ± 47.8 254.9 ± 73.9 225.3 ± 39.6
0.73
P value 0.5 0.1
Total fat, g/d 45.2 ± 17.4 49.9 ± 17.6 53.8 ± 22.2 62 ± 26.5
0.16
P value 0.42 0.31
Cholesterol, mg/d 132.7 ± 72.8 130.6 ± 62 129.7 ± 136.4 164.4 ± 174.7
0.56
P value 0.18 0.45
SFA, g/d 12.5 ± 6.3 13.5 ± 4.9 15.2 ± 6.6 16.1 ± 8.4
0.24
P value 0.52 0.82
PUFA, g/d 16.3 ± 8.8 14.5 ± 5.1 16.4 ± 9.7 17.6 ± 9.6
0.85
P value 0.94 0.33
MUFA, g/d 11 ± 5 13.1 ± 5.4 14.3 ± 8.3 21 ± 8.6
0.005
P value 0.21 0.001
Fiber, g/d 10.6 ± 3.6 11.4 ± 3 17.8 ± 7.1 16.5 ± 6.3
0.08
P value 0.81 0.56
Vitamin C, mg/d 67.7 ± 59.1 65.4 ± 42.6 151.7 ± 74.3 111.7 ± 66.7
0.01
P value 0.67 0.15
Vitamin E, mg/d 2.2 ± 2 1.8 ± 1.4 2.6 ± 1.7 3.9 ± 1.7
< 0.001
P value 0.61 0.01
Abbreviations: MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
aValues are expressed as mean ± SD.
bP values for the differences between the groups at the end of the study. Independent t test was used.
cP values for the differences within the groups from baseline to the end; the paired samples t test was used.
interleukine-6 or CRP levels in patients with metabolic syn-
drome (17). Substituting 20% of daily calorie intake with
walnut or cashews at doses ranging from 63 to 108 g/day
for eight weeks had no significant effect on CRP levels in
such patients (6). However, a Mediterranean diet enriched
with 30 g/day of mixed nuts could decrease other inflam-
matory markers in patients at high risk for CVD, while the
CRP level did not change (16). There is evidence about the
negative correlation between nut consumption and CRP
level (4), but inflammatory biomarkers are usually consid-
ered as secondary outcomes in nut feeding trials. There-
fore, the statistical power of studies was low to detect sig-
nificant differences (26).
PON is related to ApoA-I in HDL-C and prevents LDL-C
oxidation in vitro and arterial wall. In the current study,
PON-1 activity was not significantly different between the
two groups after eight weeks. In contrast, walnut im-
proved PON-1 activity in another study (23). Small sample
size or different polyphenol components in different nuts
may result in such differences.
To the authors’ best knowledge, it was the first ran-
domized, controlled-feeding trial conducted to assess the
effects of cashews consumption on atherogenic indices,
oxidative stress, and diabetes control. It was concluded
that cashews consumption by substituting 10% of total
calorie intake decreased serum insulin level and LDL-
C/HDL-C ratio in patients with T2DM, although a larger
sample size and longer duration are needed before reach-
ing conclusive results. There were some limitations to the
current study results; most importantly that it was better
to design a crossover study.
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Table 2. Anthropometric and Biochemical Measures at Baseline and the Week 8a
Variable Control (N = 21) Cashews (N = 22) P Valueb
Baseline The Week 8 Baseline The Week 8
Weight, kg 71.9 ± 9.8 71.5 ± 9.2 72.1 ± 13.2 70.7 ± 11.7
0.82
P valuec 0.17 0.12
BMI, kg/m2 28.6 ± 3.1 28.5 ± 2.9 28.7 ± 5.8 28.1 ± 5.2
0.8
P valuec 0.18 0.11
WC, cm 93.2 ± 3.7 93.1 ± 9.7 91.9 ± 11.3 91 ± 10
0.7
P valuec 0.2 0.25
FPG, mg/dL 159.9 ± 44 155.5 ± 46.5 146.04 ± 46 136 ± 55.5
0.21
P valuec 0.66 0.24
Insulind , IU/mL 10.3 ± 6.3 10.3 ± 4.2 7.7 ± 2.7 7.2 ± 2.8
0.8
P valuec 0.45 0.48
HOMA-IR 4.2 ± 2.9 3.9 ± 1.9 2.9 ± 1.6 2.6 ± 2
0.03d
P valuec 0.6 0.1
TC/HDL-C 4.4 ± 1.1 4.44 ± 1.1 4.1 ± 1.2 3.86 ± 1
0.04d
P valuec 0.8 0.21
LDL-C/HDL-Cd 2.4 ± 0.8 2.46 ± 0.6 2.1 ± 0.8 2.03 ± 0.6
0.02d
P valuec 0.6 0.33
TG/HDL.C 4.59 ± 2.4 4.08 ± 2.3 4.02 ± 3.3 3.59 ± 2.7
0.52
P valuec 0.25 0.34
hs-CRP, mg/dL 18.4 ± 19.2 19.70 ± 18.2 17.4 ± 16.1 15.80 ± 16.5
0.54
P valuec 0.4 0.26
TAC, nM/L 625.7 ± 147.7 632.55 ± 160 625.9 ± 135.7 622.9 ± 155.7
0.34
P valuec 0.51 0.67
PON-1, U/mL 116.7 ± 45 118 ± 53.6 106.4 ± 57.7 132.9 ± 64.6
0.41
P valuec 0.67 0.7
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high-sensitive C-reactive pro-
tein; PON-1, paraoxonase-1; TAC, total antioxidant capacity; TC, total cholesterol; TG, triglyceride; WC, waist circumference.
aValues are expressed as mean ± SD. Significance was considered at P < 0.05.
bP values for the intergroup differences after eight weeks intervention.
cP values for the intergroup differences from baseline to the end; paired samples t test was used.
dSignificant difference between the groups after eight weeks intervention, evaluated by ANCOVA with baseline values as covariate including age, gender, FBS, insulin,
HOMA-IR, dietary fiber, and vitamin C. vitamin C at the week 8 was also considered as covariate. Also, for TC/HDL-C, LDL/HDL, TG/HDL, PON-1, and hs-CRP, the baseline
values of each variable were considered as covariates.
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